Head and Neck Squamous Cell Carcinoma Associated with Human Papillomavirus (HPV) in a Diverse Developing Nation - Top-Institutions - MDSpire

Head and Neck Squamous Cell Carcinoma Associated with Human Papillomavirus (HPV) in a Diverse Developing Nation

  • By

  • Hans Prakash Sathasivam

  • Rohaizam Japar

  • Zanariah Alias

  • Zahirrudin Zakaria

  • Hasmah Hashim

  • Shashi Gopalan Marimuthu

  • Noraida Khalid

  • Pappathy Vairavan

  • Angeline Madatang

  • Doh Jeing Yong

  • Avatar Singh Mohan Singh

  • Abd Razak Ahmad

  • January 30, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Head and Neck Oncology
    • Molecular Pathology
    • Cancer Epidemiology

  • #2

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Head and Neck Oncology
    • Virology
    • Translational Research

  • #3

    Johns Hopkins University School of Medicine
    Johns Hopkins University School of Medicine

    Baltimore, MD

    Key Differentiators

    • Head and Neck Surgery
    • Molecular Oncology
    • Cancer Epidemiology

  • #4

    University of Pittsburgh Medical Center (UPMC)
    University of Pittsburgh Medical Center (UPMC)

    Pittsburgh, PA

    Key Differentiators

    • Head and Neck Oncology
    • Molecular Diagnostics
    • Clinical Trials

  • #5

    National Cancer Center Singapore
    National Cancer Center Singapore

    Singapore, N/A

    Key Differentiators

    • Head and Neck Oncology
    • Epidemiology
    • Molecular Pathology

Original Source(s)

Head and Neck Squamous Cell Carcinoma Associated with Human Papillomavirus (HPV) in a Diverse Developing Nation

  • by Hans Prakash Sathasivam, Rohaizam Japar, Zanariah Alias, Zahirrudin Zakaria, Hasmah Hashim, Shashi Gopalan Marimuthu, Noraida Khalid, Pappathy Vairavan, Angeline Madatang, Doh Jeing Yong, Avatar Singh Mohan Singh, Abd Razak Ahmad

  • January 30, 2026

Related Content

Trametinib as second-line therapy for advanced KRAS G12C-mutant non-small cell lung cancer: a single-center clinical analysis of 20 cases

Characteristics and risk factors of immune-related adverse events in patients receiving immune checkpoint inhibitor combination therapy

Gastric-type endocervical adenocarcinoma with Peutz-Jeghers syndrome: a case report and literature review